We performed in vitro cellular and molecular biology assessments in primary CD5+ B lymphocytes obtained from a cohort of 80 CLL patients, and we assessed, in a CLL-xenograft mouse model, the in vivo capacity of the CD47 agonist peptides to reduce tumor burden. Here, CD47 is linked to B-cell chronic lymphocytic leukemia.